ankyrin repeat and death domain containing 1AGenealiases: []
Q-omics provides the consensus-scored ANKDD1A profile across patient tissues and cancer cell-line models. ANKDD1A expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, ANKDD1A is differentially expressed in 13, with the highest sampling consensus in THCA. Additionally, ANKDD1A RNA expression shows 20,255 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight UVM, and THCA as cancer lineages where ANKDD1A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ANKDD1A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ANKDD1A survival associations across molecular data types. ANKDD1A RNA expression shows survival associations in the most cancer types (21), followed by mutation status (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ANKDD1A RNA expression–survival associations across cancer types. High ANKDD1A expression shows unfavorable associations in UVM, KICH, KIRP, LGG, COAD and KIRC. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify UVM as the clearest survival context for ANKDD1A RNA expression.
This table summarizes ANKDD1A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 1. The strongest signals are observed in THCA for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for ANKDD1A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ANKDD1A shows lower tumor expression in THCA, LUAD, UCEC and BRCA and higher tumor expression in KIRC and LIHC. The THCA box plot shows higher ANKDD1A RNA expression in normal versus tumor tissue (log2 FC = −1.386, t-test p < 0.001).
This table shows molecular features associated with ANKDD1A in patient tissues and cancer cell lines. In patient samples, ANKDD1A shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, ANKDD1A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in OVARY and LARGE_INTESTINE.
